Page 1

August 13 , 2026 Artelo BIOSCIENCES Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results Clinical and Scientific Progress Across the Pipeline Supports Multiple Upcoming Milestones SOLANA BEACH , Calif . , Aug. 13 , 2026 ( GLOBE NEWSWIRE ) -- Artelo Biosciences , Inc. ( Nasdaq : ARTL ) ( " Artelo ” or the “ Company ” ) , a clinical - stage pharmaceutical company focused on modulating lipid - signaling pathways to develop treatments for people living with cancer , pain , dermatological , or neurological conditions , today provided a business update and announced its financial and operational results for the second quarter ended June 30 , 2026 . Business Highlights ART26.12 : • Advancing Toward Multiple - Dose Clinical Evaluation : Artelo continues preparations to initiate a Phase 1 multiple ascending dose study in the fourth quarter of 2026. First- in - human data showed favorable safety and tolerability , linear and dose - proportional pharmacokinetics , exposure above projected therapeutic levels , and a wide potential therapeutic margin . Human metabolite profiling identified only three low - level metabolites , representing approximately 7 % of total drug - related exposure , with no human - specific metabolites or safety concerns . • Growing Evidence for the Treatment of Chronic Pain : New nonclinical findings broaden the program beyond chemotherapy - induced peripheral neuropathy . In an osteoarthritis model , ART26.12 provided pain relief comparable to naproxen with significantly less gastric tissue damage . Separate spinal cord injury research showed reductions in mechanical hypersensitivity and spontaneous pain behaviors . Together with Al - enabled biomarker analyses of Artelo's proprietary datasets , these findings further support the potential of selective FABP5 inhibition as a differentiated , non- opioid approach for the treatment chronic pain . ART27.13 : • More Opportunity Beyond Cancer Supportive Care : Encouraging interim Phase 2 CARES data showed improvement in body weight , lean body mass and physical activity , particularly at the highest dose . New nonclinical results in a paclitaxel - induced peripheral neuropathy model also demonstrated reductions in pain - related behaviors . In addition to conducting a fully funded Phase 2 clinical study in glaucoma , the